CoChat

Tumour‐associated macrophage‐mediated survival of myeloma cells through STAT3 activation

De Beule, Nathan, De Veirman, Kim, Maes, Ken, De Bruyne, Elke, Menu, Eline, Breckpot, Karine, De Raeve, Hendrik, Van Rampelbergh, Rian, Van Ginderachter, Jo A, Schots, Rik, Van Valckenborgh, Els, Vanderkerken, Karin · 2017 · The Journal of Pathology
Cited by 69

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Overcoming drug resistance is one of the greatest challenges in the treatment of multiple myeloma (MM). The interaction of myeloma cells with the bone marrow (BM) microenvironment is a major factor contributing to drug resistance. Tumour‐associated macrophages (TAMs) with different polarization states constitute an important component of this microenvironment. Previous studies have revealed a role of TAMs in MM cell survival and drug resistance; however, the impact of macrophage polarization (anti‐tumoural ‘M1’ versus pro‐tumoural ‘M2’‐like phenotype) in this process has not yet been described. Here, the presence of TAMs was confirmed in BM sections from MM patients, both at diagnosis and relapse, with two M2 markers, CD163 and CD206. By following different TAM subpopulations during disease progression in the syngeneic murine 5T33MM model, we demonstrated a decrease in the number of inflammatory monocytes and an increase in the number of M2‐oriented TAMs in BM. Co‐culture experiments demonstrated that macrophages provide a survival benefit to myeloma cells that is maintained after treatment with several classes of anti‐myeloma agent (melphalan and bortezomib); the greatest effect was observed with M2‐polarized macrophages. The pro‐survival effect was associated with activation of the STAT3 pathway in 5T33MM cells, less cleavage of caspase‐3, and thus less apoptosis. AZD1480, an ATP‐competitive JAK2 inhibitor, abrogated the observed TAM‐mediated MM cell survival, and partially inhibited resistance to bortezomib. Despite having only a small quantitative impact on myeloid cells in vivo, AZD1480 treatment alone and in combination with bortezomib significantly reduced tumour load. In conclusion, M2 TAMs are present in the MM microenvironment, and contribute to MM cell survival and protection from drug‐induced apoptosis. As a result of TAM‐induced activation of the STAT3 pathway, 5T33MM cells are sensitized to AZD1480 treatment. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.4860

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
De Beule, N., De Veirman, K., Maes, K., De Bruyne, E., Menu, E., Breckpot, K., De Raeve, H., Van Rampelbergh, R., Van Ginderachter, J. A., Schots, R., Van Valckenborgh, E., & Vanderkerken, K.
Venue
The Journal of Pathology
Publisher
Wiley
Published
2017-01-30
Volume
241
Issue
4
Pages
534-546
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W2566175157
Cited by
69
References
4
FWCI
3.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.